Tesamorelin: A GHRH Analogue in Research
Related Product
Tesamorelin
Overview
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), a 44-amino acid hypothalamic peptide that stimulates the pituitary gland to secrete growth hormone (GH). Tesamorelin consists of the full 44-amino acid sequence of human GHRH with a trans-3-hexenoic acid group attached to the N-terminus, which increases its stability against enzymatic degradation.
Mechanism of Action
Tesamorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of GH. Unlike direct GH administration, tesamorelin preserves the physiological pulsatile pattern of GH secretion, which is important for maintaining the normal feedback regulation of the GH/IGF-1 axis.
Research Applications
Tesamorelin has been studied in several research contexts:
- Visceral adipose tissue: Clinical studies have examined tesamorelin's effects on visceral fat accumulation, particularly in HIV-associated lipodystrophy models.
- Cognitive function: Research has examined the relationship between GH/IGF-1 signalling and cognitive performance in aging models.
- Metabolic parameters: Effects on lipid profiles, insulin sensitivity, and body composition have been studied in various populations.
Regulatory Status
Tesamorelin (brand name Egrifta) has received FDA approval for a specific therapeutic indication. As a research compound, it is studied under laboratory conditions to better understand GHRH receptor biology and GH axis regulation.
Research use of tesamorelin must comply with all applicable institutional, local, and federal regulations.
Research Disclaimer: This article is provided for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. All products are intended strictly for laboratory research and are not approved for human consumption.